Quick Answer
BeOne Medicines Ltd. reported Long Term Debt of $961.91 million for the year ending 2025.
- BeOne Medicines Ltd. showed an increase of +477.8% in Long Term Debt from 2024 to 2025.
- This data is from BeOne Medicines Ltd.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $9.57 million | Q2 2018: $51.47 million | Q3 2018: $40.82 million | Q1 2019: $77.48 million | Q2 2019: $84.49 million | Q3 2019: $104.23 million | Q1 2020: $81.91 million | Q2 2020: $131.49 million | Q3 2020: $151.55 million | Q1 2021: $1.26 billion | Q2 2021: $194.86 million | Q3 2021: $200.91 million | Q1 2022: $201.61 million | Q2 2022: $185.21 million | Q3 2022: $1.48 billion | Q1 2023: $1.42 billion | Q2 2023: $1.50 billion | Q3 2023: $1.48 billion | Q1 2024: $199.03 million | Q2 2024: $1.35 billion | Q3 2024: $1.32 billion | Q1 2025: $160.16 million | Q2 2025: $146.09 million.
- Over the full 10 years of available data (2016 to 2025), BeOne Medicines Ltd.'s Long Term Debt has grown by 5,465.3%.
- Historical annual values: Fiscal year 2025: $961.91 million | Fiscal year 2024: $166.48 million | Fiscal year 2023: $197.62 million | Fiscal year 2022: $1.44 billion | Fiscal year 2021: $1.29 billion | Fiscal year 2020: $183.64 million | Fiscal year 2019: $580.00 million | Fiscal year 2018: $40.79 million | Fiscal year 2017: $9.22 million | Fiscal year 2016: $17.28 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: